Changing the Standard of Care for Patients with RET+ mNSCLC or Advanced Thyroid Cancer ~ 9/29/22


Hear from an expert during this presentation, which will cover the following topics: 

  • Identification and management of certain RET+ cancers 

  • Overview of GAVRETO, including clinical trial data, safety information, and dosing recommendations 

  • Hypothetical patient case(s) from identification to management 

  • Support programs available for your patients


Changing the Standard of Care for Patients With RET+ mNSCLC or Advanced Thyroid Cancers

Presented by: Martin Dietrich, MD, PhD

Medical Oncologist Florida Cancer Specialists & Research Institute


Thursday, September 29, 2022, 06:00 PM EDT

Grill 23,

161 Berkeley Street, Boston, ma, 02116


You may register for this program by calling or texting Sharon Lively at (857) 275-0573 or emailing slively@blueprintmedicines.com.


INDICATIONS

GAVRETO is indicated for the treatment of:

• Adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test

• Adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy

• Adult and pediatric patients 12 years of age and older with advanced or metastatic


RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate) These indications are approved under accelerated approval based on overall response rate and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in confirmatory trials.


SELECT SAFETY INFORMATION

Interstitial Lung Disease (ILD)/Pneumonitis occurred in 10% of patients who received GAVRETO, including 2.7% with Grade 3/4, and 0.5% with fatal reactions. Monitor for pulmonary symptoms indicative of ILD/pneumonitis. Withhold GAVRETO and promptly investigate for ILD in any patient who presents with acute or worsening of respiratory symptoms (e.g., dyspnea, cough, and fever). Withhold, reduce dose or permanently discontinue GAVRETO based on severity of confirmed ILD. Please see additional Select Safety Information throughout, and click here to see the full Prescribing Information for GAVRETO. 1 Information for virtual programs only: Zoom link will be provided following registration. Information for in-person programs only: By accepting our invitation to attend this event, you confirm that: (a) neither you nor those in your household are experiencing COVID-19 symptoms or are in quarantine; (b) within the past 14 days you have not been diagnosed with, suspected to have, or exposed to, COVID-19; (c) you will fully comply with all requested COVID-19 and contact tracing protocols related to the event; (d) even with the protocols, participation in the event presents a risk of exposure to COVID-19; and (e) you will not participate in the event in person if you are unable to re-confirm all of the above as of the day of the event.


Download or review full event flyer here.


GAVRETO sept 29
.pdf
Download PDF • 606KB

63 views0 comments